In the UK, patients who have been unresponsive to traditional, licensed treatments that are used to treat and manage ankylosing spondylitis may be considered eligible for medical cannabis treatments at Releaf.
This is because of the effect cannabis-derived treatments can have on common symptoms people with ankylosing spondylitis encounter, such as pain, inflammation and disturbed sleep. The effects medical cannabis can have on inflammation and pain are well noted and evidenced, and scientific research in this area is extensive compared to cannabis’ other associated effects.
For example, in 2021 a systematic review that analysed 26 scientific articles concluded numerous chemicals contained within cannabis, including CBD and CBG, have anti-inflammatory properties, and these can be harnessed therapeutically.
Another case series published in 2023 analysed the responses of 3148 Australian patients who were using medical cannabis. Over 74% of those involved were using cannabis-derived treatments to manage their pain, and after commencing treatments, significant improvements were seen in all 8 domains of health included on the SF-36 health survey.
These domains are physical functioning, physical role limitations, bodily pain, energy and vitality, social functioning, emotional role limitations, and general health perceptions. It is important to note that medical cannabis is not a ‘cure all’ and it is not a suitable option for everyone. However, for those struggling with conventional treatments, medical cannabis may be an option worth considering. Find out if you may be eligible today.